EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy

Fawaz O Alenazy, Maan H Harbi, Dean P Kavanagh, Joshua Price, Paul Brady, Oscar Hargreaves, Paul Harrison, Alexandre Slater, Alok Tiwari, Phillip L R Nicolson, Derek L Connolly, Paulus Kirchhof und 5 weitere

Journal of Thrombosis and Haemostasis · 2023

DOI: 10.1016/j.jtha.2023.07.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023. Verfasst von Fawaz O Alenazy und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Laboratory Sciences, College of Ap…. Hauptthemen laut MEDLINE: Plaque, Atherosclerotic, Acute Coronary Syndrome, ST Elevation Myocardial Infarction, Thrombosis. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, British Heart Foundation, BHF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Aspirin and platelet P2Y12 inhibitors, such as ticagrelor, suboptimally inhibit microvascular thrombosis during ST-elevation myocardial infarction. Glycoprotein (GP) IIb/IIIa inhibitors may further inhibit this but cause excessive bleeding. OBJECTIVES: We investigated whether combination of glenzocimab, a GPVI inhibitor, with aspirin and ticagrelor provides additional antithrombotic effects, as GPVI has a critical role in atherothrombosis but minimal involvement in hemostasis. METHODS: We investigated the effects of glenzocimab (monoclonal antibody Fab fragment) using blood from healthy donors and patients with acute coronary syndrome treated with aspirin and ticagrelor. Platelets were stimulated with multiple agonists, including atherosclerotic plaque, from patients undergoing carotid endarterectomy. RESULTS: Aspirin and ticagrelor partially inhibited atherosclerotic plaque-induced platelet aggregation by 48% compared with control (34 ± 3 vs 65 ± 4 U; P 95% when combined with aspirin and ticagrelor (3 ± 1 vs 65 ± 4 U; P < .001). Glenzocimab reduced platelet aggregation, adhesion, and thrombin generation when added to blood of aspirin- and ticagrelor-treated patients with acute coronary syndrome. Glenzocimab shared several antithrombotic effects with the GPIIb/IIIa inhibitor eptifibatide with less effect on general hemostasis assessed by rotational thromboelastometry. In a murine intravital model of ST-elevation myocardial infarction, genetic depletion of GPVI reduced microvascular thrombosis. CONCLUSION: Addition of glenzocimab to aspirin and ticagrelor enhances platelet inhibition via multiple mechanisms of atherothrombosis. Compared with a GPIIb/IIIa inhibitor, glenzocimab shares multiple antithrombotic effects, with less inhibition of mechanisms involved in general hemostasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plaque, AtheroscleroticAcute Coronary SyndromeST Elevation Myocardial InfarctionThrombosisHumansAnimalsMicePlatelet Aggregation InhibitorsTicagrelorFibrinolytic AgentsPlatelet ActivationAspirinPlatelet Glycoprotein GPIIb-IIIa ComplexAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

GPVIacute coronary syndromesantiplatelet therapyatherosclerotic plaquepharmacologyplatelets thrombosistranslational studies

Substanzen

Platelet Aggregation InhibitorsTicagrelorFibrinolytic AgentsAspirinPlatelet Glycoprotein GPIIb-IIIa ComplexglenzocimabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka, Saudi Arabia.
  • Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; Pharmacology and Toxicology Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; Department of Cardiology, Sandwell and West Birmingham Hospitals National Health Service (NHS) Trust, Birmingham, United Kingdo…
  • Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.
  • Department of Vascular Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Förderung

  • Wellcome Trust
  • British Heart Foundation
  • BHF
  • Academy of Medical Sciences

Zitieren

APA

Alenazy, F. O., Harbi, M. H., Kavanagh, D. P., Price, J., Brady, P., Hargreaves, O., Harrison, P., Slater, A., Tiwari, A., Nicolson, P. L. R., Connolly, D. L., Kirchhof, P., Kalia, N., Jandrot-Perrus, M., Mangin, P. H., Watson, S. P., & Thomas, M. R. (2023). Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2023.07.018

Vancouver

Alenazy FO, Harbi MH, Kavanagh DP, Price J, Brady P, Hargreaves O, et al. Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy. Journal of Thrombosis and Haemostasis. 2023. doi:10.1016/j.jtha.2023.07.018

BibTeX
@article{Alenazy2023,
  author = {Alenazy, Fawaz O and Harbi, Maan H and Kavanagh, Dean P and Price, Joshua and Brady, Paul and Hargreaves, Oscar and Harrison, Paul and Slater, Alexandre and Tiwari, Alok and Nicolson, Phillip L R and Connolly, Derek L and Kirchhof, Paulus and Kalia, Neena and Jandrot-Perrus, Martine and Mangin, Pierre H and Watson, Steve P and Thomas, Mark R},
  title = {Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2023},
  doi = {10.1016/j.jtha.2023.07.018}
}
Kostenlos starten →